Named for a type of duck but definitely lacking any waddle in its step, Merganser Biotech Inc. made a big splash in the rare disease pond by reeling in a $28 million series A round led by the Novartis Venture Fund and joined by Frazier Healthcare, Sutter Hill Ventures and Osage University Partners.